Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer

Cancer Science

Volumn 97, Issue 6, 2006, Pages 484-491

  Matsukawa, Yasuko ^a   Semba, Shuho ^a   Kato, Hirotaka ^a   Ito, Akihiko ^a   Yanagihara, Kazuyoshi ^b   Yokozaki, Hiroshi ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ENHANCER OF ZESTE HOMOLOG 2 PROTEIN; MESSENGER RNA; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE COURSE; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL SIGNIFICANCE; STOMACH CANCER; STOMACH CARCINOGENESIS; STOMACH MUCOSA; STOMACH SURGERY; SURVIVAL RATE; TUMOR VOLUME; UNIVARIATE ANALYSIS;

AGED; BLOTTING, WESTERN; CELL LINE, TUMOR; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 33744519651     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2006.00203.x     Document Type: Article

References (43)

1. Yasui W, Yokozaki H, Shimamoto F, Tahara H, Tahara E. Molecular-pathological diagnosis of gastrointestinal tissues and its contribution to cancer histopathology. Pathol Int 1999; 49: 763-74.
2. Yasui W, Oue N, Kuniyasu H, Ito R, Tahara E, Yokozaki H. Molecular diagnosis of gastric cancer: Present and future. Gastric Cancer 2001; 4: 113-21.
3. Yokozaki H, Yasui W, Tahara E. Genetic and epigenetic changes in stomach cancer. Int Rev Cytol 2001; 204: 49-95.
4. Chen H, Rossier C, Antonarakis SE. Cloning of a human homolog of the Drosophila enhancer of zeste gene (EZH2) that maps to chromosome 21q22.2. Genomics 1996; 38: 30-7.
5. Cao R, Wang L, Wang H et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 2002; 298: 1039-43.
6. Czermin B, Melfi R, McCabe D, Seitz V, Imhof A, Pirrotta V. Drosophila enhancer of Zeste/ESC complexes have a histone H3 methyltransferase activity that marks chromosomal Polycomb sites. Cell 2002; 111: 185-96.
7. Kuzmichev A, Nishioka K, Erdjument-Bromage H, Tempst P, Reinberg D. Histone methyltransferase activity associated with a human multiprotein complex containing the enhancer of Zeste protein. Genes Dev 2002; 16: 2893-905.
8. Muller J, Hart CM, Francis NJ et al. Histone methyltransferase activity of a Drosophila Polycomb group repressor complex. Cell 2002; 111: 197-208.
9. Kuzmichev A, Jenuwein T, Tempst P, Reinberg D. Different EZH2-containing complexes target methylation of histone H1 or nucleosomal histone H3. Mol Cell 2004; 14: 183-93.
10. Tonini T, Bagella L, D'Andrilli G, Claudio PP, Giordano A. Ezh2 reduces the ability of HDAC1-dependent pRb2/p130 transcriptional repression of cyclin A. Oncogene 2004; 23: 4930-7.
11. Rhodes DR, Sanda MG, Otte AP, Chinnaiyan AM, Rubin MA. Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. J Natl Cancer Inst 2003; 95: 661-8.
12. Cao R, Zhang Y. The functions of E (Z)/EZH2-mediated methylation of lysine 27 in histone H3. Curr Opin Genet Dev 2004; 14: 155-64.
13. Varambally S, Dhanasekaran SM, Zhou M et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002; 419: 624-9.
14. Kleer CG, Cao Q, Varambally S et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 2003; 100: 11606-11.
15. Raaphorst FM, Meijer CJ, Fieret E et al. Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene. Neoplasia 2003; 5: 481-8.
16. Sudo T, Utsunomiya T, Mimori K et al. Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma. Br J Cancer 2005; 92: 1754-8.
17. Weikert S, Christoph F, Kollermann J et al. Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas. Int J Mol Med 2005; 16: 349-53.
18. Arisan S, Buyuktuncer ED, Palavan-Unsal N, Caskurlu T, Cakir OO, Ergenekon E. Increased expression of EZH2, a polycomb group protein, in bladder carcinoma. Urol Int 2005; 75: 252-7.
19. Raaphorst FM, van Kemenade FJ, Blokzijl T et al. Coexpression of BMI-1 and EZH2 polycomb group genes in Reed-Sternberg cells of Hodgkin's disease. Am J Pathol 2000; 157: 709-15.
20. Visser HP, Gunster MJ, Kluin-Nelemans HC et al. The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma. Br J Haematol 2001; 112: 950-8.
21. van Kemenade FJ, Raaphorst FM, Blokzijl T et al. Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. Blood 2001; 97: 3896-901.
22. Dukers DF, van Galen JC, Giroth C et al. Unique polycomb gene expression pattern in Hodgkin's lymphoma and Hodgkin's lymphoma-derived cell lines. Am J Pathol 2004; 164: 873-81.
23. Yanagihara K, Seyama T, Tsumuraya M, Kamada N, Yokoro K. Establishment and characterization of human signet ring cell gastric carcinoma cell lines with amplification of the c-myc oncogene. Cancer Res 1991; 51: 381-6.
24. Yanagihara K, Ito A, Toge T, Numoto M. Antiproliferative effects of isoflavones on human cancer cell lines established from the gastrointestinal tract. Cancer Res 1993; 53: 5815-21.
25. Hojo H. Establishment of cultured cell lines of human stomach cancer -origin and their morphological characteristics. Niigata Igakukai Zasshi 1977; 91: 737-52 (in Japanese).
26. Motoyama T, Hojo H, Watanabe H. Comparison of seven cell lines derived from human gastric carcinomas. Acta Pathol Jpn 1986; 36: 65-83.
27. Ochiai A, Yasui W, Tahara E. Growth-promoting effect of gastrin on human gastric carcinoma cell line TMK-1. Jpn J Cancer Res 1985; 76: 1064-71.
28. Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma- 2nd English Edition. Gastric Cancer 1998; 1: 10-24.
29. Sellers WR, Loda M. The EZH2 polycomb transcriptional repressor - a marker or mover of metastatic prostate cancer? Cancer Cell 2002; 2: 349-50.
30. Foster CS, Falconer A, Dodson AR et al. Transcription factor E2F3 overexpressed in prostate cancer independently predicts clinical outcome. Oncogene 2004; 23: 5871-9.
31. Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. Embo J 2003; 22: 5323-35.
32. Chen H, Tu SW, Hsieh JT. Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer. J Biol Chem 2005; 280: 22437-44.
33. Su IH, Dobenecker MW, Dickinson E et al. Polycomb group protein ezh2 controls actin polymerization and cell signaling. Cell 2005; 121: 425-36.
34. Lambrechts A, Van Troys M, Ampe C. The actin cytoskeleton in normal and pathological cell motility. Int J Biochem Cell Biol 2004; 36: 1890-909.
35. Thor AD, Edgerton SM, Liu S, Moore DH 2nd, Kwiatkowski DJ. Gelsolin as a negative prognostic factor and effector of motility in erbB-2-positive epidermal growth factor receptor-positive breast cancers. Clin Cancer Res 2001; 7: 2415-24.
36. Adachi Y, Yasuda K, Inomata M, Sato K, Shiraishi N, Kitano S. Pathology and prognosis of gastric carcinoma: Well versus poorly differentiated type. Cancer 2000; 89: 1418-24.
37. Hyung WJ, Noh SH, Lee JH et al. Early gastric carcinoma with signet ring cell histology. Cancer 2002; 94: 78-83.
38. Arai T, Esaki Y, Inoshita N et al. Pathologic characteristics of gastric cancer in the elderly. a retrospective study of 994 surgical patients. Gastric Cancer 2004; 7: 154-9.
39. Nakamura K, Ogoshi K, Makuuchi H. Focus on the histologic diversity in primary and lymph node lesions and the outcome of gastric cancer. J Exp Clin Cancer Res 2004; 23: 15-23.
40. Kim JP, Kim YW, Yang HK, Noh DY. Significant prognostic factors by multivariate analysis of 3926 gastric cancer patients. World J Surg 1994; 18: 872-8.
41. Soreide JA, van Heerden JA, Burgart LJ, Donohue JH, Sarr MG, Ilstrup DM. Surgical aspects of patients with adenocarcinoma of the stomach operated on for cure. Arch Surg 1996; 131: 481-8.
42. Kajiyama Y, Tsurumaru M, Udagawa H et al. Prognostic factors in adenocarcinoma of the gastric cardia: Pathologic stage analysis and multivariate regression analysis. J Clin Oncol 1997; 15: 2015-21.
43. Yasuda K, Shiraishi N, Suematsu T, Yamaguchi K, Adachi Y, Kitano S. Rate of detection of lymph node metastasis is correlated with the depth of submucosal invasion in early stage gastric carcinoma. Cancer 1999; 85: 2119-23.